Stockreport

New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026

Ascendis Pharma A/S - Ordinary Share  (ASND) 
Last ascendis pharma a/s - ordinary share earnings: 11/18 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ascendispharma.com
PDF COPENHAGEN, Denmark, March 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from its pivotal ApproaCH Trial showing that childr [Read more]